AGP Picks
View all

European Ledger: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Ledger.

Press releases published on September 30, 2026

Anortech Confirms Deep-Water Port Site at Gronne Bjerg Anorthosite Project, Greenland
Elevra Lithium 2026 Annual General Meeting Information
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Terra Innovatum Announces Upcoming Investor Conference Schedule
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards
Leapwork Play Reaches General Availability, Adding Enterprise Governance and Evidence to Playwright Test Automation
Sekoia Elevate macht autonome Cyberabwehr zur Realität: von Sicherheitsmeldungen zur Bewertung in 99 Sekunden
Sekoia Elevate brings autonomous cyber defense to life: from security data to verdict in 99 seconds
Sekoia Elevate hace realidad la ciberdefensa autónoma: de los datos de seguridad al veredicto en 99 segundos
Sekoia Elevate rende concreta la difesa informatica autonoma: dai dati di sicurezza al verdetto in 99 secondi
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
American Lithium Minerals, Inc. Announces Completion of PCAOB Audit and Planned Uplisting to OTCQB in Fourth Quarter 2026
Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update
R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application
More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

European Ledger

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.